Galapagos Says First patient Randomized In GALACELA, A Phase 2 Systemic Lupus Erythematosus (SLE) Trial With GLPG3667
Portfolio Pulse from Benzinga Newsdesk
Galapagos has announced the initiation of the GALACELA Phase 2 trial for Systemic Lupus Erythematosus (SLE) with GLPG3667. The first patient has been randomized in the trial.
August 28, 2023 | 8:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Galapagos has initiated a Phase 2 trial for SLE with GLPG3667, which could potentially lead to a new treatment option for SLE patients.
The initiation of a Phase 2 trial indicates that the company has seen promising results in early-stage studies. This could potentially lead to a new treatment option for SLE, which would be a significant development for the company. However, it's important to note that the drug is still in the early stages of development and there are many hurdles to overcome before it can be approved and brought to market.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100